Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShare-based Compensation (IS)Shares Outstanding (Weighted Average)
Others
Ratios

Addex Therapeutics (ADXN) EPS (Weighted Average and Diluted): 2022-2024

Historic EPS (Weighted Average and Diluted) for Addex Therapeutics (ADXN) over the last 3 years, with Dec 2024 value amounting to $0.08.

  • Addex Therapeutics' EPS (Weighted Average and Diluted) rose 27.50% to -$0.02 in Q1 2024 from the same period last year, while for Mar 2024 it was -$0.13, marking a year-over-year increase of 47.86%. This contributed to the annual value of $0.08 for FY2024, which is 151.04% up from last year.
  • Per Addex Therapeutics' latest filing, its EPS (Weighted Average and Diluted) stood at $0.08 for FY2024, which was up 151.04% from -$0.16 recorded in FY2023.
  • In the past 5 years, Addex Therapeutics' EPS (Weighted Average and Diluted) ranged from a high of $0.08 in FY2024 and a low of -$0.48 during FY2022.
  • For the 3-year period, Addex Therapeutics' EPS (Weighted Average and Diluted) averaged around -$0.19, with its median value being -$0.16 (2023).
  • Data for Addex Therapeutics' EPS (Weighted Average and Diluted) shows a peak YoY skyrocketed of 151.04% (in 2024) over the last 5 years.
  • Yearly analysis of 3 years shows Addex Therapeutics' EPS (Weighted Average and Diluted) stood at -$0.48 in 2022, then surged by 67.67% to -$0.16 in 2023, then spiked by 151.04% to $0.08 in 2024.